First-Line Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab Continue to Demonstrate OS Benefit in Patients with Advanced Oesophageal Squamous Cell Carcinoma By Ogkologos - September 1, 2026 7 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the 5-year follow-up of the CheckMate 648 study Source RELATED ARTICLESMORE FROM AUTHOR NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer MOST POPULAR FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer... June 10, 2026 FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive,... September 9, 2026 Adding More Mushrooms to Your Diet May Decrease Your Risk of... April 21, 2021 A Painful Breast Lump May Be Mistaken For Cancer When It’s... July 15, 2020 Load more HOT NEWS Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients... As Use of Genomic Data Expands in Cancer Care, Patients Share... A Nurse’s Love For Oncology Patients Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer
